+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07156175

Randomized, Double-Blind Study Comparing SAR444336 and Placebo in Adults With Microscopic Colitis in Clinical Remission Receiving Budesonide

Led by Sanofi · Updated on 2026-10-26

54

Participants Needed

24

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of SAR444336 in adults with microscopic colitis who are in clinical remission and currently receiving budesonide therapy. This is a Phase 2, randomized, double-blind, placebo-controlled study designed to assess whether SAR444336 can help maintain steroid-free clinical remission in this population. Participants will be randomly assigned to receive several subcutaneous injections of either SAR444336 or placebo while continuing their prescribed budesonide dose. The overall study duration is approximately 32 weeks, with primary outcomes measured up to week 24 and safety monitoring extending to week 28. During the study, participants will undergo regular assessments to monitor clinical remission status, drug plasma levels, and possible adverse events. Researchers will track treatment-emergent adverse events, anti-drug antibody development, and study withdrawal reasons. The trial includes close safety and efficacy monitoring, with the primary outcome focusing on sustained steroid-free remission up to week 24.

CONDITIONS

Brief Title

A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission

Research Team

T

Trial Transparency email recommended (Toll free for US & Canada)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here